Affinia Therapeutics
- Sector
- Biotech
- Founded
- 2019
- Latest Form D
- $13.3M, Oct 2025
- Total capital
- $170M
- Federal grants
- None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
- Private capital raised
- $170M
- 4 Form D · last Oct 2025
- 12 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 0
- 40 pending
Capital timeline
Latest events
- Private capital raisedForm D · SEC · 4th filing$13.3M
- Private capital raisedForm D · SEC · 3rd filing$110M
- Private capital raisedForm D · SEC · 2nd filing$38.5M
- Private capital raisedForm D · SEC · 1st filing$8.3M
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Founders and team
From SEC Form D filings- Carole FaigDirectorNamed in SEC Form D filings
- Caroline StoutDirectorNamed in SEC Form D filings
- Charles AlbrightExecutive OfficerNamed in SEC Form D filings
- David GrayzelDirectorNamed in SEC Form D filings
- Diana BrainardDirectorNamed in SEC Form D filings
- Edward MathersDirectorNamed in SEC Form D filings
Show all 19 people
- Elliot SigalDirectorNamed in SEC Form D filings
- Elliott SigalDirectorNamed in SEC Form D filings
- Laura RichmanExecutive OfficerNamed in SEC Form D filings
- Luc VandenbergheDirectorNamed in SEC Form D filings
- Paula CobbExecutive OfficerNamed in SEC Form D filings
- Petra KaufmannExecutive OfficerNamed in SEC Form D filings
- Rami DaoudExecutive OfficerNamed in SEC Form D filings
- Rick ModiExecutive Officer, DirectorNamed in SEC Form D filings
- Robert AboudExecutive OfficerNamed in SEC Form D filings
- Robert JohnsonExecutive OfficerNamed in SEC Form D filings
- Robert WeisskoffDirectorNamed in SEC Form D filings
- Rob MayExecutive OfficerNamed in SEC Form D filings
- Sean NolanDirectorNamed in SEC Form D filings
What it has protected
USPTO · 0 granted of 40- PendingRecombinant Aavs With Improved Tropism And SpecificityUSPTOApplication 19122709
- PendingRecombinant Aavs With Improved Tropism And SpecificityUSPTOApplication 19104215
- PendingRecombinant Aavs With Improved Tropism And SpecificityUSPTOApplication 18264919
Show all 40 patent records
- Recombinant Aavs With Improved Tropism And SpecificityJun 4, 2026 · Application 19122709Pending
- Recombinant Aavs With Improved Tropism And SpecificityMar 5, 2026 · Application 19104215Pending
- Recombinant Aavs With Improved Tropism And SpecificityApr 11, 2024 · Application 18264919Pending
- Recombinant Aav For Treatment Of Neural DiseaseFeb 2, 2023 · Application 17717858Pending
- Recombinant Aav For Treatment Of Cardiac DiseasesApplication 63723079Pending
- Recombinant Aavs With Improved Tropism And SpecificityApplication 63696654Pending
- Recombinant Aavs With Improved Tropism And SpecificityApplication PCTUS2024029714Pending
- Recombinant Aav For Treatment Of Cardiac DiseasesApplication 63643759Pending
- Recombinant Aavs With Improved Tropism And SpecificityApplication 63643890Pending
- Recombinant Aavs With Improved Tropism And SpecificityApplication 63639578Pending
- Plasmid System For Production Of Recombinant Adenoassociated VirusApplication 63565528Pending
- Recombinant Aavs With Improved Tropism And SpecificityApplication 63625790Pending
- Recombinant Aavs With Improved Tropism And SpecificityApplication PCTUS2023077340Pending
- Recombinant Aavs With Improved Tropism And SpecificityApplication PCTUS2023072424Pending
- Recombinant Aavs With Improved Tropism And SpecificityApplication 63502871Pending
- Recombinant Aavs With Improved Tropism And SpecificityApplication 63502525Pending
- Recombinant Aavs With Improved Tropism And SpecificityApplication 63502577Pending
- Recombinant Aavs With Improved Tropism And SpecificityApplication 63502595Pending
- Recombinant Aavs With Improved Tropism And SpecificityApplication 63482874Pending
- Recombinant Aavs With Improved Tropism And SpecificityApplication 63482758Pending
- Recombinant Aavs With Improved Tropism And SpecificityApplication 63482754Pending
- Recombinant Aavs With Improved Tropism And SpecificityApplication 63482776Pending
- Recombinant Aavs With Improved Tropism And SpecificityApplication 19484821Pending
- Recombinant Aavs With Improved Tropism And SpecificityApplication 63380170Pending
- Recombinant Aavs With Improved Tropism And SpecificityApplication 63371744Pending
- Recombinant Aavs With Improved Tropism And SpecificityApplication 63371743Pending
- Recombinant Aavs With Improved Tropism And SpecificityApplication 63371715Pending
- Recombinant Aav For Treatment Of Neural DiseaseApplication PCTUS2022024262Pending
- Recombinant Aavs With Improved Tropism And SpecificityApplication PCTUS2022015842Pending
- Recombinant Aav For Treatment Of Neural DiseaseApplication 63306735Pending
- Recombinant Aav For Treatment Of Neural DiseaseApplication PCTUS2021063889Pending
- Recombinant Aavs With Improved Tropism And SpecificityApplication 63290517Pending
- Recombinant Aav For Treatment Of Neural DiseaseApplication 63290544Pending
- Recombinant Aav For Treatment Of Neural DiseaseApplication 63290543Pending
- Recombinant Aav For Treatment Of Neural DiseaseApplication PCTUS2021063882Pending
- Recombinant Aav For Treatment Of Neural DiseaseApplication 63217449Pending
- Recombinant AAV for Treatment of Neural DiseasesApplication 63186655Pending
- Recombinant AAVs with improved tropism and specificityApplication 63186641Pending
- Recombinant AAV for Treatment of Neural DiseasesApplication 63173992Pending
- Compositions and Methods for Treatment of X-Linked Myotubular Myopathy (XLMTM)Application 63173998Pending
Related companies, and why
- Eikon TherapeuticsSimilar federal contract value in Biotech · null in contracts
- Perspective Therapeutics, Inc.Similar federal contract value in Biotech · null in contracts
- Accent TherapeuticsSimilar federal contract value in Biotech · null in contracts
- PRECISION BIOSCIENCES INCSimilar federal contract value in Biotech · null in contracts
- Antares TherapeuticsSimilar federal contract value in Biotech · null in contracts
- Caldera TherapeuticsSimilar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .